226 related articles for article (PubMed ID: 22903545)
21. Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM.
Murphy TL; Murphy KM
Annu Rev Immunol; 2010; 28():389-411. PubMed ID: 20307212
[TBL] [Abstract][Full Text] [Related]
22. High BTLA Expression Likely Contributes to Contraction of the Regulatory T Cell Subset in Lupus Disease.
Aubergeon L; Sawaf M; Felten R; Gottenberg JE; Dumortier H; Monneaux F
Front Immunol; 2021; 12():767099. PubMed ID: 34899718
[TBL] [Abstract][Full Text] [Related]
23. High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.
M'Hidi H; Thibult ML; Chetaille B; Rey F; Bouadallah R; Nicollas R; Olive D; Xerri L
Am J Clin Pathol; 2009 Oct; 132(4):589-96. PubMed ID: 19762537
[TBL] [Abstract][Full Text] [Related]
24. Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway.
Sakoda Y; Park JJ; Zhao Y; Kuramasu A; Geng D; Liu Y; Davila E; Tamada K
Blood; 2011 Feb; 117(8):2506-14. PubMed ID: 21220749
[TBL] [Abstract][Full Text] [Related]
25. Herpes Simplex Virus 1 Latency and the Kinetics of Reactivation Are Regulated by a Complex Network of Interactions between the Herpesvirus Entry Mediator, Its Ligands (gD, BTLA, LIGHT, and CD160), and the Latency-Associated Transcript.
Wang S; Ljubimov AV; Jin L; Pfeffer K; Kronenberg M; Ghiasi H
J Virol; 2018 Dec; 92(24):. PubMed ID: 30282707
[TBL] [Abstract][Full Text] [Related]
26. Cutting Edge: the BTLA-HVEM regulatory pathway interferes with protective immunity to intestinal Helminth infection.
Breloer M; Hartmann W; Blankenhaus B; Eschbach ML; Pfeffer K; Jacobs T
J Immunol; 2015 Feb; 194(4):1413-6. PubMed ID: 25595777
[TBL] [Abstract][Full Text] [Related]
27. Dual inhibition of BTLA and PD-1 can enhance therapeutic efficacy of paclitaxel on intraperitoneally disseminated tumors.
Sun WZ; Lin HW; Chen WY; Chien CL; Lai YL; Chen J; Chen YL; Cheng WF
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37463789
[TBL] [Abstract][Full Text] [Related]
28. The intrahepatic expression and distribution of BTLA and its ligand HVEM in patients with HBV-related acute-on-chronic liver failure.
Xu H; Cao D; Guo G; Ruan Z; Wu Y; Chen Y
Diagn Pathol; 2012 Oct; 7():142. PubMed ID: 23067542
[TBL] [Abstract][Full Text] [Related]
29. Molecular basis for herpesvirus entry mediator recognition by the human immune inhibitory receptor CD160 and its relationship to the cosignaling molecules BTLA and LIGHT.
Kojima R; Kajikawa M; Shiroishi M; Kuroki K; Maenaka K
J Mol Biol; 2011 Nov; 413(4):762-72. PubMed ID: 21959263
[TBL] [Abstract][Full Text] [Related]
30. Clinical Significance of BTLA and HVEM Expression on Circulating CD4
Song HF; Chen XJ; Tang PJ; Xu P; Huang ZY; Wang XF
Viral Immunol; 2022 May; 35(4):291-302. PubMed ID: 35196150
[TBL] [Abstract][Full Text] [Related]
31. BTLA interaction with HVEM expressed on CD8(+) T cells promotes survival and memory generation in response to a bacterial infection.
Steinberg MW; Huang Y; Wang-Zhu Y; Ware CF; Cheroutre H; Kronenberg M
PLoS One; 2013; 8(10):e77992. PubMed ID: 24205057
[TBL] [Abstract][Full Text] [Related]
32. The expression and anatomical distribution of BTLA and its ligand HVEM in rheumatoid synovium.
Shang Y; Guo G; Cui Q; Li J; Ruan Z; Chen Y
Inflammation; 2012 Jun; 35(3):1102-12. PubMed ID: 22179929
[TBL] [Abstract][Full Text] [Related]
33. Soluble B and T lymphocyte attenuator possesses antitumor effects and facilitates heat shock protein 70 vaccine-triggered antitumor immunity against a murine TC-1 cervical cancer model in vivo.
Han L; Wang W; Fang Y; Feng Z; Liao S; Li W; Li Y; Li C; Maitituoheti M; Dong H; Lai Z; Gao Q; Xi L; Wu M; Wang D; Zhou J; Meng L; Wang S; Ma D
J Immunol; 2009 Dec; 183(12):7842-50. PubMed ID: 19923459
[TBL] [Abstract][Full Text] [Related]
34. Balancing co-stimulation and inhibition with BTLA and HVEM.
Murphy KM; Nelson CA; Sedý JR
Nat Rev Immunol; 2006 Sep; 6(9):671-81. PubMed ID: 16932752
[TBL] [Abstract][Full Text] [Related]
35. Potentiating vaccine immunogenicity by manipulating the HVEM/BTLA pathway and other co-stimulatory and co-inhibitory signals of the immune system.
Lasaro MO; Ertl HC
Hum Vaccin; 2009; 5(1):6-14. PubMed ID: 18927514
[TBL] [Abstract][Full Text] [Related]
36. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.
Gonzalez LC; Loyet KM; Calemine-Fenaux J; Chauhan V; Wranik B; Ouyang W; Eaton DL
Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1116-21. PubMed ID: 15647361
[TBL] [Abstract][Full Text] [Related]
37. BTLA-derived peptides as inhibitors of BTLA/HVEM complex formation - design, synthesis and biological evaluation.
Kuncewicz K; Bojko M; Battin C; Karczyńska A; Sieradzan A; Sikorska E; Węgrzyn K; Wojciechowicz K; Wardowska A; Steinberger P; Rodziewicz-Motowidło S; Spodzieja M
Biomed Pharmacother; 2023 Sep; 165():115161. PubMed ID: 37473684
[TBL] [Abstract][Full Text] [Related]
38. T Cells Expressing CAR Equipped With Extracellular Domain of BTLA Are Effective Against HVEM-over-expressing Melanoma Cell Lines.
Kim Y; Kim JE; Lee DY; Choi JU; Park JS; Lee HK; Choi SU; Park S; Park CH
Anticancer Res; 2023 Aug; 43(8):3419-3427. PubMed ID: 37500142
[TBL] [Abstract][Full Text] [Related]
39. Selective blockade of herpesvirus entry mediator-B and T lymphocyte attenuator pathway ameliorates acute graft-versus-host reaction.
del Rio ML; Jones ND; Buhler L; Norris P; Shintani Y; Ware CF; Rodriguez-Barbosa JI
J Immunol; 2012 May; 188(10):4885-96. PubMed ID: 22490863
[TBL] [Abstract][Full Text] [Related]
40. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator.
Sedy JR; Gavrieli M; Potter KG; Hurchla MA; Lindsley RC; Hildner K; Scheu S; Pfeffer K; Ware CF; Murphy TL; Murphy KM
Nat Immunol; 2005 Jan; 6(1):90-8. PubMed ID: 15568026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]